High-normal blood pressure stage I hypertension
Conditions
Interventions
During the run-in period, subjects will receive daily 10 g of palm super olein
oil. During the intervention period subjects receive either 10 ml of high oleic
sunflower oil or flaxseed oil. All oils
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Aged between 40-70 years - Quetelet-index between 25-35 kg/m2 - High-normal blood pressure or stage I hypertension - Mean serum total cholesterol
Exclusion criteria
Exclusion criteria: - Unstable body weight (weight gain or loss >2 kg in the past 3 months) - Use of antihypertensive or anticoagulant medication - Indication for treatment with cholesterol-lowering drugs according to the Dutch Cholesterol Consensus - Usage of non-steroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen) and not able or willing to stop taking them from at least 4 weeks prior to the study - Use of medication or a diet known to affect serum lipid or glucose metabolism - Women taking oral contraceptives or estrogen replacement therapy - Women lactating, pregnant or intend to become pregnant during study - Active cardiovascular disease like congestive heart failure or recent ( 10 h/w - Not possible or difficult to venipuncture as evidenced during the screening visits - Use of an investigational product within the previous 30 days - Not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study - Not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the change in 24h-ambulatory mean arterial pressure (MAP) | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives are to study the effects of flaxseed oil on 1) night, day and early morning 24h-ambulatory MAP, 2) systolic, diastolic and MAP office blood pressure, 3) postprandial flow mediated dilatation (FMD) and 4) the fatty-acid profile of plasma phospholipids | — |
Countries
Netherlands
Outcome results
None listed